Real-world data from the CIBMTR registry at #EHA2026 reinforce the impact of liso-cel in relapsed/refractory #MCL.
✅ ORR of 89% and CR rate of 79%
✅ Median DOR, PFS, and OS not reached
✅ Safety profile consistent with pivotal trial results
Learn more: www.onclive.com/view/real-wo...
Real-world data show liso-cel drives high response rates and durable benefit in relapsed/refractory MCL, including high-risk patients.
